The report shows that China's gene industry is in a period of rapid growth
Number of views：
Xinhuanet Beijing, February 2 (reporter Li Bin) The Blue Book of the Gene Industry 2021, jointly compiled by Genomics Research Institute, a third-party research institute, and 14 other institutions, was released to the public recently. The report shows that with the iteration of underlying technology, product design and changes in application scope, the gene industry is in a period of rapid growth.
First NGS liquid biopsy product approved by FDA; Gene sequencing to the single-cell level; Domestic sequencing platforms have gradually matured and are replacing them in some fields... Over the past year, major breakthroughs have been made in gene-related technologies.
"2021 Gene Industry Blue Book" is divided into six parts, including "2020 Gene Industry Development Overview", "Industry Ecology", "Gene Industry Aggregation and Industry Overview", "Capital Market Analysis", "Industrial Innovation Cases" and "2021 Development Trend". The blue book points out that the gene industry is in a period of high growth. In terms of product dimension, in China, since the non-invasive prenatal genetic testing products were approved to be marketed in 2014, the marketed genetic products are mainly concentrated in the category of medical devices and new drugs. Medical instruments include gene chip scanner, digital PCR or quantitative fluorescence PCR, sequencer, mass spectrometer as well as supporting production raw materials and reagents consumable materials, as well as detection kit products focusing on pre-implantation aneuploidy screening and gene diagnosis, tumor companion diagnosis (targeted gene detection) and tumor early screening. Gene therapy based on a new generation of gene editing technology has not yet been approved in China and is in the early stages of clinical trials. Global gene synthesis and DNA data storage are still in the development stage.
Lu Daru, deputy dean of the School of Life Sciences at Fudan University, pointed out in the preface: "The gene industry is the basic pillar of the life industry and the source and commanding point of the biomedical industry. "The development of the gene industry is the result of discoveries in gene science and rapid advances in gene technology."
In terms of genetic technology infrastructure, the industry still needs equipment such as sequencers with lower testing costs, shorter testing cycles, better performance and more user friendliness, and bioinformatics analysis needs to be more standardized, embedded in hardware, form a knowledge base and have the ability to enrich annotations and accelerate interpretation, according to the blue paper. And take advantage of the new generation of information technology to achieve more convenient cloud applications, mobile applications, Internet of Things applications and data security.
"At present, high-throughput whole gene sequencing is gradually being applied to the clinical stage. We see that gene and other technological means and advantages are essentially 'big data of life and health', and the construction of such achievements requires the collaborative coupling of multiple platforms such as medical informatization and new drug research and development." "Fan Jia, an academician of the Chinese Academy of Sciences and president of the Zhongshan Hospital affiliated to Fudan University, wrote in the preface.
Since 2017, Genomics has continuously released annual gene industry research reports, aiming to promote the popularization, transformation, innovation and entrepreneurship of gene technology.
